• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis.

作者信息

Gissel C, Götz G, Repp H

机构信息

Junior Chair of Health Economics, Justus Liebig University Giessen, Licher Str. 62, Giessen, 35394, Germany.

Chair for Industrial Organization, Regulation and Antitrust, Justus Liebig University Giessen, Giessen, Germany.

出版信息

Z Rheumatol. 2017 Mar;76(2):185. doi: 10.1007/s00393-016-0256-2.

DOI:10.1007/s00393-016-0256-2
PMID:28084541
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5344950/
Abstract
摘要

相似文献

1
Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis.回复：关于改善类风湿关节炎中阿达木单抗已报道的成本效益的必要性
Z Rheumatol. 2017 Mar;76(2):185. doi: 10.1007/s00393-016-0256-2.
2
Need for improvements in reported cost effectiveness of adalimumab in rheumatoid arthritis.
Z Rheumatol. 2017 Mar;76(2):183-184. doi: 10.1007/s00393-016-0255-3.
3
The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.生物疗法在类风湿关节炎临床实践中的经济负担：意大利患者皮下注射抗 TNFα 治疗的成本效益分析。
Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1147-52. doi: 10.1177/039463200902200434.
4
Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.肿瘤坏死因子-α抑制剂作为类风湿关节炎一线用药的成本效益
Pharmacoeconomics. 2006;24(12):1221-32. doi: 10.2165/00019053-200624120-00006.
5
Cost-effectiveness of anti-tumor necrosis factor agents.抗肿瘤坏死因子药物的成本效益
Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S65-70.
6
Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.在希腊，对中重度活动期类风湿关节炎患者，采用培塞利珠单抗联合甲氨蝶呤进行成本-效用分析。
Rheumatol Int. 2017 Sep;37(9):1441-1452. doi: 10.1007/s00296-017-3736-z. Epub 2017 May 18.
7
Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.英国、法国和德国生物性改善病情抗风湿药在停用依那西普后治疗类风湿关节炎的真实世界疗效
Clin Ther. 2017 Aug;39(8):1618-1627. doi: 10.1016/j.clinthera.2017.06.009. Epub 2017 Jul 17.
8
Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.与类风湿关节炎常规治疗相比，疾病活动度指导下的阿达木单抗或依那西普减量及停药：开放标签、随机对照、非劣效性试验。
BMJ. 2015 Apr 9;350:h1389. doi: 10.1136/bmj.h1389.
9
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.接受抗TNF-α药物治疗的类风湿关节炎患者发生带状疱疹的风险。
JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.
10
Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.阿达木单抗、依那西普和英夫利昔单抗强化治疗类风湿关节炎的疗效：侧重于剂量的队列研究系统评价。
Semin Arthritis Rheum. 2013 Oct;43(2):144-51. doi: 10.1016/j.semarthrit.2013.01.007. Epub 2013 Jul 6.

本文引用的文献

1
EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.根据英国和瑞典偏好集得出的类风湿关节炎患者使用阿巴西普、利妥昔单抗、托珠单抗或肿瘤坏死因子抑制剂治疗后的欧洲五维健康量表效用增益：瑞典南部的一项前瞻性队列研究
Arthritis Res Ther. 2016 Feb 19;18:51. doi: 10.1186/s13075-016-0950-0.